A Drug Safety Evaluation of Dapagliflozin for Diabetic Nephropathies in Patients with Cardiovascular Risk.
Publication/Presentation Date
2-2-2025
Abstract
INTRODUCTION: Diabetic nephropathy isa significant concern for patients with cardiovascular disease. Dapagliflozin,an SGLT2 inhibitor, has emerged as a promising therapeutic approach to managingdiabetic nephropathy and reducing cardiovascular risk.
AREAS COVERED: This reviewencompasses the research and literature search methodology, including clinicaltrials and real-world evidence, assessing the safety profile of Dapagliflozinin patients with diabetic nephropathy and cardiovascular risk.
EXPERT OPINION: Dapagliflozin, an SGLT2 inhibitor, hasredefined patient-centric care by simultaneously improving glycemic control,cardiovascular health, and renal outcomes in individuals with type 2 diabetes,cardiovascular disease, and nephropathy.
ISSN
1744-764X
Published In/Presented At
Sood, A., Sawhney, A., Borokhovsky, B., Vyas, A. V., & Gupta, R. (2025). A Drug Safety Evaluation of Dapagliflozin for Diabetic Nephropathies in Patients with Cardiovascular Risk. Expert opinion on drug safety, 10.1080/14740338.2025.2462671. Advance online publication. https://doi.org/10.1080/14740338.2025.2462671
Disciplines
Medicine and Health Sciences
PubMedID
39895014
Department(s)
Department of Medicine, Cardiology Division, Fellows and Residents
Document Type
Article
